First Time Loading...
Y

YS Biopharma Co Ltd
NASDAQ:YS

Watchlist Manager
YS Biopharma Co Ltd
NASDAQ:YS
Watchlist
Price: 0.97 USD 1.89% Market Closed
Updated: May 12, 2024
Section:
 

Wall Street
Price Targets

YS Price Targets Summary
YS Biopharma Co Ltd

Wall Street analysts forecast YS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for YS is 4.26 USD with a low forecast of 3.13 USD and a high forecast of 5.51 USD.

YS Lowest Forecast
Wall Street Target
3.13 USD
223% Upside
YS Average Forecast
Wall Street Target
4.26 USD
339% Upside
YS Highest Forecast
Wall Street Target
5.51 USD
468% Upside
Lowest
Price Target
3.13 USD
223% Upside
Average
Price Target
4.26 USD
339% Upside
Highest
Price Target
5.51 USD
468% Upside
YS Biopharma Co Ltd Competitors:
Price Targets
PYC
PYC Therapeutics Ltd
262% Upside
B
BLRX
BioLine RX Ltd
82% Downside
REGN
Regeneron Pharmaceuticals Inc
10% Upside
P
214450
PharmaResearch Co Ltd
21% Upside
PYC
PYC Therapeutics Ltd
262% Upside
B
BLRX
BioLine RX Ltd
82% Downside
REGN
Regeneron Pharmaceuticals Inc
10% Upside
P
214450
PharmaResearch Co Ltd
21% Upside
LGND
Ligand Pharmaceuticals Inc
36% Upside
I
688382
InventisBio Co Ltd
67% Upside
DTIL
Precision BioSciences Inc
216% Upside
300439
MedicalSystem Biotechnology Co Ltd
124% Upside

Revenue
Forecast

Revenue Estimate
YS Biopharma Co Ltd

The compound annual growth rate of YS Biopharma Co Ltd's revenue for the next 4 years is 29%.

N/A
Past Growth
29%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
YS Biopharma Co Ltd

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
YS Biopharma Co Ltd

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

See Also

Summary
YS intrinsic value, competitors valuation, and company profile.
DCF Valuation
YS stock valuation using Discount Cash Flow valuation method.
Relative Valuation
YS stock valuation using valuation multiples.
Wall Street Estimates
YS price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
YS stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is YS's stock price target?
Price Target
4.26 USD

According to Wall Street analysts, the average 1-year price target for YS is 4.26 USD with a low forecast of 3.13 USD and a high forecast of 5.51 USD.

What is YS Biopharma Co Ltd's Revenue forecast?
Projected CAGR
29%

The compound annual growth rate of YS Biopharma Co Ltd's revenue for the next 4 years is 29%.

ALPHA SPREAD
Join more than 136,500+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.